



**Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year
Ending February 28, 2025 [Japanese GAAP]**

October 10 2024

Company name: Hisamitsu Pharmaceutical Co., Inc.
 Stock exchange listing: Tokyo, Nagoya, Fukuoka
 Securities code: 4530
 URL: <https://global.hisamitsu/>
 Representative: NAKATOMI Kazuhide, President & CEO
 Contact: ISOBE Yuichi, Executive Officer, Department General Manager of Corporate Strategy Planning and Business Development
 TEL: +81-3-5293-1704
 Scheduled date of filing semi-annual securities report: Oct.11, 2024
 Scheduled date of dividend payment: Nov. 7, 2024
 Preparation of supplementary materials for financial results: Yes
 Holding of financial results meeting: Yes (for institutional investors and analysts, etc.)

(Amounts are rounded down to the nearest millions of yen)

**1. Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending February 28, 2025
(March 1, 2024 to August 31, 2024)**

(1) Consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended Aug. 31, 2024	75,456	12.7	9,006	7.3	10,788	(7.3)	9,098	8.1
Six months ended Aug. 31, 2023	66,977	12.3	8,396	70.9	11,640	31.2	8,417	29.4

(Note) Comprehensive income: Six months ended Aug. 31, 2024 21,073 millions of yen [(1.5)%]
 Six months ended Aug. 31, 2023 21,400 millions of yen [4.2%]

	Profit per share	Diluted profit per share
	yen	yen
Six months ended Aug. 31, 2024	122.71	122.55
Six months ended Aug. 31, 2023	108.34	108.23

(2) Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio
	Millions of yen	Millions of yen	%
As of Aug. 31, 2024	350,477	275,927	78.0
As of Feb. 29, 2024	328,779	267,082	80.5

(Reference) Shareholders' equity: As of Aug. 31, 2024 273,201 millions of yen
 As of Feb. 29, 2024 264,541 millions of yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Fourth quarter	Total
	yen	yen	yen	yen	yen
Year ended Feb. 29, 2024	—	42.50	—	42.50	85.00
Year ending Feb. 28, 2025	—	45.00			
Year ending Feb. 28, 2025 (Forecast)			—	45.00	90.00

(Note) Revisions to the most recently announced dividends forecast: No

2. Breakdown of annual dividend forecast for the fiscal year 2025

Ordinary dividend	86.00 yen
Commemorative dividend	4.00 yen (A commemorative dividend for the 90th anniversary of the launch of SALONPAS [®])

3. Consolidated Earnings Forecast for the Fiscal Year Ending February 28, 2025 (March 1, 2024 to February 28, 2025)

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Profit per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Full year	152,000	7.3	14,500	10.1	18,900	(3.8)	15,800	13.1	213.10

(Note) Revisions to the most recently announced consolidated forecast: No

*Notes

- (1) Changes in significant subsidiaries during the period
(Changes in specified subsidiaries resulting in changes in scope of consolidation) : None
- (2) Application of special accounting methods for preparation of interim consolidated financial statements : Yes
- (3) Changes in accounting policies, changes in accounting estimates, and restatement
- 1) Changes in accounting policies due to revision of accounting standards : None
 - 2) Changes in accounting policies other than 1) above : None
 - 3) Changes in accounting estimates : None
 - 4) Restatement : None
- (4) The number of shares outstanding (common stock)
- 1) Total number of shares outstanding at the end of the period (including treasury stock)

As of Aug. 31, 2024	85,164,895 shares
As of Feb. 29, 2024	85,164,895 shares
 - 2) Total number of treasury stock at the end of the period

As of Aug. 31, 2024	11,822,153 shares
As of Feb. 29, 2024	9,421,781 shares
 - 3) Average number of shares outstanding during the period

Six months ended Aug. 31, 2024	74,142,951 shares
Six months ended Aug. 31, 2023	77,697,690 shares

*Semi-annual financial results reports are not subjected to review.

*Explanation for appropriate use of financial forecasts and other special notes

Among this document, the forecasts based on the plan may changes due to uncertain factors. Therefore, the actual operating results may differ from the company's view.

Financial settlement briefings for institutional investors and analysts will be held on October 10, 2024. Presentation materials of financial results will be posted promptly on the company's website after the financial settlement briefings.

Interim Consolidated Financial Statements

(1) Interim Consolidated Balance sheets

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 29, 2024)	End of the current interim accounting period (As of Aug. 31, 2024)
Assets		
Current assets		
Cash and deposits	112,459	113,572
Notes and accounts receivable - trade, and contract assets	43,237	51,878
Securities	12,862	9,164
Merchandise and finished goods	11,501	12,253
Work in process	842	1,109
Raw materials and supplies	8,833	9,642
Other	4,542	9,725
Allowance for doubtful accounts	(254)	(302)
Total current assets	194,022	207,043
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	15,851	27,408
Other, net	33,611	31,420
Total property, plant and equipment	49,462	58,828
Intangible assets		
Sales rights	347	323
Goodwill	1,444	1,369
Other	5,039	4,761
Total intangible assets	6,831	6,454
Investments and other assets		
Investment securities	67,121	65,711
Other	11,548	12,646
Allowance for doubtful accounts	(207)	(207)
Total investments and other assets	78,462	78,151
Total non-current assets	134,756	143,433
Total assets	328,779	350,477

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 29, 2024)	End of the current interim accounting period (As of Aug. 31, 2024)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	9,612	13,101
Electronically recorded obligations - operating	6,651	8,957
Short-term loans payable	1,071	1,071
Income taxes payable	1,889	3,775
Provision for bonuses	1,831	1,345
Other	24,881	30,352
Total current liabilities	45,938	58,603
Non-current liabilities		
Long-term loans payable	76	46
Net defined benefit liability	8,598	8,663
Other	7,083	7,236
Total non-current liabilities	15,758	15,946
Total liabilities	61,696	74,550
Net assets		
Shareholders' equity		
Capital stock	8,473	8,473
Capital surplus	2,361	2,361
Retained earnings	242,578	248,509
Treasury shares	(36,993)	(45,896)
Total shareholders' equity	216,420	213,447
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	22,052	22,282
Revaluation reserve for land	3,403	3,403
Foreign currency translation adjustment	21,621	33,177
Remeasurements of defined benefit plans	1,042	890
Total accumulated other comprehensive income	48,120	59,753
Share acquisition rights	334	373
Non-controlling interests	2,205	2,352
Total net assets	267,082	275,927
Total liabilities and net assets	328,779	350,477

(2) Interim Consolidated Statements of Income and Comprehensive Income

Interim Consolidated Statements of Income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2023 – Aug. 31, 2023)	Current Fiscal Year (Mar. 1, 2024 – Aug. 31, 2024)
Net sales	66,977	75,456
Cost of sales	28,330	31,047
Gross profit	38,646	44,408
Selling, general and administrative expenses	30,250	35,402
Operating profit	8,396	9,006
Non-operating income		
Interest income	1,128	1,461
Dividend income	567	648
Foreign exchange gains	1,305	—
Other	335	446
Total non-operating income	3,336	2,555
Non-operating expenses		
Interest expenses	7	16
Share of loss of entities accounted for using equity method	22	137
Foreign exchange losses	—	582
Loss on cancellation of insurance policies	47	—
Other	15	36
Total non-operating expenses	91	773
Ordinary profit	11,640	10,788
Extraordinary income		
Gain on disposal of non-current assets	—	12
Gain on sale of investment securities	—	2,303
Total extraordinary income	—	2,315
Extraordinary losses		
Loss on disposal of non-current assets	2	2
Total extraordinary losses	2	2
Profit before income taxes	11,638	13,101
Income taxes	2,967	3,700
Profit	8,671	9,401
Profit attributable to non-controlling interests	253	303
Profit attributable to owners of parent	8,417	9,098

Interim Consolidated Statements of comprehensive income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2023 – Aug. 31, 2023)	Current Fiscal Year (Mar. 1, 2024 – Aug. 31, 2024)
Profit	8,671	9,401
Other comprehensive income		
Valuation difference on available-for-sale securities	4,422	200
Foreign currency translation adjustment	8,303	11,594
Remeasurements of defined benefit plans, net of tax	(93)	(156)
Share of other comprehensive income of entities accounted for using equity method	97	33
Total other comprehensive income	12,729	11,672
Comprehensive income	21,400	21,073
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	21,036	20,731
Comprehensive income attributable to non-controlling interests	364	342

(3) Interim Consolidated Statements of Cash Flows

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2023 – Aug. 31, 2023)	Current Fiscal Year (Mar. 1, 2024 – Aug. 31, 2024)
Cash flows from operating activities		
Profit before income taxes	11,638	13,101
Depreciation	2,473	2,914
Amortization of goodwill	—	75
Increase (decrease) in retirement benefit liability	72	48
Increase (decrease) in allowance for doubtful accounts	14	40
Interest and dividend income	(1,695)	(2,109)
Loss (gain) on cancellation of insurance policies	44	—
Interest expenses	7	16
Share of loss (profit) of entities accounted for using equity method	22	137
Loss (gain) on sales of investment securities	—	(2,303)
Decrease (increase) in trade receivables	(248)	(6,666)
Decrease (increase) in inventories	(342)	(605)
Increase (decrease) in trade payables	1,079	5,025
Other, net	(4,792)	(1,134)
Subtotal	8,274	8,540
Interest and dividends received	1,499	1,928
Interest paid	(7)	(16)
Income taxes paid	(1,906)	(2,187)
Payments of retirement benefits for directors (and other officers)	(7)	(7)
Net cash provided by (used in) operating activities	7,851	8,256
Cash flows from investing activities		
Decrease (increase) in time deposits	14,943	10,611
Decrease (increase) in short-term investment securities	171	—
Purchase of property, plant and equipment	(4,686)	(10,041)
Purchase of intangible assets	(4)	(30)
Purchase of investment securities	(8)	(8)
Proceeds from sales of investment securities	—	3,690
Proceeds from cancellation of insurance funds	27	—
Other, net	1	22
Net cash provided by (used in) investing activities	10,443	4,242
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	(2)	—
Repayments of long-term borrowings	(33)	(29)
Purchase of treasury shares	(1,336)	(8,902)
Dividends paid	(3,287)	(3,217)
Dividends paid to non-controlling interests	(108)	(131)
Other, net	(73)	(68)
Net cash provided by (used in) financing activities	(4,841)	(12,350)
Effect of exchange rate change on cash and cash equivalents	2,307	2,102
Net increase (decrease) in cash and cash equivalents	15,761	2,251
Cash and cash equivalents at beginning of period	65,424	66,366
Cash and cash equivalents at end of period	81,186	68,617



Our commitments originate from each individual's determination to "start something good for ecology (eco)!"

Hisamitsu Pharmaceutical has designed the "HELLO! eco!" mark as a symbol of its environmental activities,

and products that have met the ecology standards that our company has established will display the "HELLO! eco!" mark sequentially.

Hisamitsu.